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The N-end rule relates the in vivo half-life of a protein to the
identity of its N-terminal residue. Primary destabilizing N-terminal
residues (Ndp) are recognized directly by the targeting machinery.
The recognition of secondary destabilizing N-terminal residues
(Nds) is preceded by conjugation of an Ndp residue to Nds of a
polypeptide substrate. In eukaryotes, ATE1-encoded arginyl-trans-
ferases (RD,E,C*-transferases) conjugate Arg (R), an Ndp residue, to
Nds residues Asp (D), Glu (E), or oxidized Cys residue (C*). Ubiquitin
ligases recognize the N-terminal Arg of a substrate and target the
(ubiquitylated) substrate to the proteasome. In prokaryotes such as
Escherichia coli, Ndp residues Leu (L) or Phe (F) are conjugated, by
the aat-encoded LeuPhe-transferase (LFK,R-transferase), to N-
terminal Arg or Lys, which are Nds in prokaryotes but Ndp in
eukaryotes. In prokaryotes, substrates bearing the Ndp residues
Leu, Phe, Trp, or Tyr are degraded by the proteasome-like ClpAP
protease. Despite enzymological similarities between eukaryotic
RD,E,C*-transferases and prokaryotic LFK,R-transferases, there is no
significant sequelogy (sequence similarity) between them. We
identified an aminoacyl-transferase, termed Bpt, in the human
pathogen Vibrio vulnificus. Although it is a sequelog of eukaryotic
RD,E,C*-transferases, this prokaryotic transferase exhibits a ‘‘hy-
brid’’ specificity, conjugating Ndp Leu to Nds Asp or Glu. Another
aminoacyl-transferase, termed ATEL1, of the eukaryotic pathogen
Plasmodium falciparum, is a sequelog of prokaryotic LFK,R-trans-
ferases (Aat), but has the specificity of eukaryotic RD,E,C*-trans-
ferases (ATE1). Phylogenetic analysis suggests that the substrate
specificity of R-transferases arose by two distinct routes during the
evolution of eukaryotes.
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A protein substrate of the ubiquitin (Ub) system, which controlsthe levels of many intracellular proteins, is conjugated to Ub
through the action of three enzymes, E1, E2, and E3. The sub-
strate’s degradation signal (degron) is recognized by E3 (1–4). A
ubiquitylated protein bears a covalently linked poly-Ub chain and
is degraded by the 26S proteasome (5, 6). An essential determinant
of one class of degrons, called N-degrons, is a substrate’s destabi-
lizingN-terminal residue. The set of destabilizing residues in a given
cell type yields a rule, called theN-end rule, which relates the in vivo
half-life of a protein to the identity of its N-terminal residue (7–12).
In eukaryotes, the N-degron consists of three main determinants,
a destabilizingN-terminal residue of a substrate, its internal Lys (K)
residue(s) (the site of formation of a poly-Ub chain), and a
conformationally flexible region(s) in the vicinity of these deter-
minants (7, 13, 14).
The N-end rule has a hierarchic structure (Fig. 1). In eukaryotes,
N-terminal Asn (N) and Gln (Q) are tertiary destabilizing residues
in that they function, through enzymatic deamidation (15, 16), to
yield the secondary destabilizingN-terminal residues (Nds)Asp (D)
and Glu (E) (Fig. 1A). The activity of Asp and Glu requires their
conjugation, by ATE1-encoded isoforms of Arg-tRNA-protein
transferase (RD,E,C*-transferase, where C* is oxidized cysteine
residue), to Arg (R), one of the primary destabilizing N-terminal
residues (Ndp) (11, 17, 18). The latter are recognized by the E3 Ub
ligases of the N-end rule pathway, called N-recognins (Fig. 1A) (7,
9, 10, 12). Inmammals, the set of destabilizing residues that function
through their arginylation contains not only N-terminal Asp and
Glu, but also N-terminal Cys (C), which is arginylated after its nitric
oxide (NO)-dependent oxidation (Fig. 1A) (11, 18).
The functions of the eukaryotic N-end rule pathway include the
control of peptide import (through the conditional degradation of
import’s repressor) (8, 9), the fidelity of chromosome segregation
(through the degradation of a conditionally produced cohesin’s
fragment) (19), the regulation of apoptosis (through the degrada-
tion of a caspase-processed inhibitor of apoptosis) (20, 21), the
regulation of meiosis (10), leaf senescence in plants (22), and
cardiovascular development in mammals (11, 18, 23). The latter
function is likely to be mediated in part by the arginylation-
dependent degradation of RGS4, RGS5, and RGS16, a set of
GTPase-activating proteins that down-regulate the signaling by
specific G proteins and are themselves down-regulated by the
N-end rule pathway, at rates controlled by NO and oxygen (11, 18,
23). The Johanson-Blizzard syndrome, a human genetic disease, is
caused by the absence of UBR1, one of the E3 N-recognins of the
N-end rule pathway (Fig. 1A) (24).
Although prokaryotes lack Ub conjugation and Ub itself, they
contain the (Ub-independent) N-end rule pathway, which has been
so far characterized only in Escherichia coli (Fig. 1B) (25, 26). The
pathway’s physiological functions in prokaryotes are unknown. In
E. coli, the Ndp residues Leu (L) or Phe (F) are conjugated, by the
aat-encoded LeuPhe-tRNA-protein transferase (LFK,R-
transferase), to N-terminal Arg or Lys, which are the Nds residues
in prokaryotes but Ndp residues in eukaryotes (Fig. 1 A and B) (7,
25, 26). Reporter substrates bearing the Ndp residues Leu, Phe, Trp
(W), orTyr (Y) are targeted for degradation byClpAP (27–30), one
of several proteasome-like proteases in E. coli. ClpS, a 12-kDa
adaptor protein specific forClpAP, is an essential component of the
E. coli N-end rule pathway, where it functions as the N-recognin
(Fig. 1B) (31).
Although eukaryotic RD,E,C*-transferases (ATE1) and prokary-
otic LFK,R-transferases (Aat) mediate analogous enzymatic reac-
tions (Fig. 1), there is no significant sequelogy (sequence similarity)
between these sets of enzymes. [In this terminology (32), sequelog
and spalog denote, respectively, a sequence that is similar, to a
specified extent, to another sequence, and a 3D structure that is
similar, to a specified extent, to another 3D structure. These terms
and their derivatives allow separate, single-word notations for
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sequence and spatial similarities. Their other advantage is evolu-
tionary neutrality. The sequelog terminology complements the
existing one (homolog, ortholog, paralog) by making the initial
designation of a sequence similarity (sequelogy) rigorous, i.e.,
evolutionarily neutral, while still allowing later designations to
involve homology or related terms, if their employment is justified
by evidence (32).]
We describe here a prokaryotic aminoacyl-transferase (aa-
transferase) termed Bpt (bacterial protein transferase) and char-
acterized in the human pathogen Vibrio vulnificus. This Gram-
negative -proteobacterium is naturally found in marine
environments, including shellfish, and can cause gastrointestinal
and bloodstream infections in humans. These infections can be
severe, and occasionally fatal, in patients with compromised im-
mune system, iron overload, or hepatic disease (ref. 33 and refer-
ences therein). In contrast to E. coli Aat, the Bpt aa-transferase is
a sequelog (32) of eukaryotic RD,E,C*-transferases (ATE1), but is
shown here to exhibit a ‘‘hybrid’’ specificity: it conjugates the Ndp
residue Leu to Nds residues Asp or Glu (Fig. 1C). Yet another
transferase, termed ATEL1, of the eukaryotic pathogen Plasmo-
dium falciparum (malaria parasite), is a sequelog of the prokaryotic
LFK,R-transferase (Aat), but is shown to have the specificity of the
eukaryotic RD,E,C*-transferase (ATE1) (Fig. 1D). We discuss the
evolution of theUb system and possible functions of aa-transferases
and the prokaryotic N-end rule pathway.
Results and Discussion
An aa-Transferase in V. vulnificus. Through searches in databases we
found that some prokaryotes, other than E. coli, contain proteins
that are sequelogs of eukaryotic ATE1 (see Introduction for the
Fig. 1. The N-end rule pathways and the activities of aa-transferases, the Bpt LD,E-transferase of V. vulnificus (a prokaryotic pathogen) and the ATEL1
RD,E-transferase of P. falciparum (an eukaryotic pathogen). (A) The N-end rule pathway in mammals. N-terminal residues are indicated by single-letter
abbreviations for amino acids. Yellow ovals denote the rest of a protein substrate. C* denotes oxidized N-terminal Cys, produced in reactions mediated by NO,
with subsequent arginylation of C* by ATE1-encoded isoforms of Arg-tRNA-protein transferase (RD,E,C*-transferase) (11). The type-1 and type-2 primary
destabilizing N-terminal residues are recognized by multiple E3 Ub ligases (N-recognins) of the N-end rule pathway that share the UBR motif (12). Through their
other substrate-binding sites, these E3 enzymes also recognize internal (non-N-terminal) degradation signals (degrons) in other substrates of the N-end rule
pathway, denoted by a larger yellow oval. (B) The E. coli N-end rule pathway (7, 25, 26). Although the purified Aat LFK,R-transferase is capable of conjugating
either L (Leu) or F (Phe), the conjugated residue in vivo (in E. coli) is largely L (26). (C) The V. vulnificus N-end rule pathway, characterized in the present work,
including the aa-transferase Bpt (LD,E-transferase). ClpS was demonstrated to be the N-recognin of the E. coli N-end rule pathway (31); its similar function in V.
vulnificus is an inferred one at present. (D) The putative N-end rule pathway ofP. falciparumand the ATEL1 aa-transferase. A question mark denotes the expected
but unproven features of this pathway in P. falciparum, where the only characterized component thus far is ATEL1.








terms and notations used).We denoted the corresponding genes as
bpt to distinguish them from eukaryotic transferase genes (ATE1)
(11, 18) and prokaryotic aat genes (25, 26). Remarkably, the
sequenced genomeof the humanprokaryotic pathogenV. vulnificus
(NC004459 and NC004460) was found to encode Aat (LFK,R-
transferase) and Bpt in a two-transferase operon (NC004459;
Vv12124), in which the ORF of bpt begins within the stop codon
of the preceding aat ORF (Fig. 2A). Partial overlaps of adjacent
ORFs in an operon were observed with other prokaryotic genes as
well (34).
To examine the recognitionconjugation specificity of V. vulni-
ficus Bpt, an Aat-lacking strain of E. coli (aat::minitet, TS351) (26)
was transformed with plasmids expressing the yeast deubiquitylat-
ing enzyme UBP1 and either the intact V. vulnificus aat-bpt operon
or its derivativeswith deletions (Fig. 2A) (seeMaterials andMethods
and Supporting Text, which is published as supporting information
on the PNAS web site). By cleaving, nearly cotranslationally, after
the last residue ofUb in aUb fusion, theUBP1 enzyme enabled the
Ub fusion technique in E. coli (25, 35), thereby making possible the
in vivo production of X--galactosidase (gal) reporter proteins in
which N-terminal X was a desired residue.
Bpt Transferase Has a Hybrid RecognitionConjugation Specificity.
Asp-gal and Glu-gal are normally long-lived in E. coli, because
N-terminal Asp and Glu are stabilizing residues in this prokaryote,
in that they are not recognized by either theAat LFK,R-transferase
or the rest of the E. coli N-end rule pathway (25, 26, 31). Previous
work (13, 17, 36) has shown that the steady-state level of an X-gal
reporter is a sensitive measure of its metabolic stability. Remark-
ably, Asp-gal and Glu-gal became short-lived in Aat-lacking E.
coli that expressed V. vulnificus Bpt, irrespective of the presence or
absence of V. vulnificus Aat (Fig. 2 B–E). This result indicated that
V. vulnificus Bpt, similarly to eukaryotic ATE1 (and in contrast to
prokaryotic Aat) recognized N-terminal Asp and Glu. This result
also indicated that an amino acid conjugated by V. vulnificus Bpt
could not be Arg, but was expected, instead, to be either Leu, Phe,
Trp, or Tyr. The reason for this conclusion is that any one of the
latter four residues, if made N-terminal, would be directly recog-
nized as a Ndp residue by the ClpS–ClpAP targetingproteolytic
complex (Fig. 1B) (31). Because the degradation of Asp-gal and
Glu-gal, the substrates of V. vulnificusBpt, was not affected by the
absence of V. vulnificusAat, and because a converse omission of V.
vulnificus Bpt from E. coli expressing V. vulnificus Aat did not
perturb the degradation of Aat substrates Arg-gal and Lys-gal
(Fig. 2 B–E), a physical interaction between Bpt and Aat, even if it
normally occurred, would not be required for the activities of these
enzymes. Neither coimmunoprecipitation tests nor a cAMP-based
two-hybrid in vivo assay in E. coli (37) suggested a physical inter-
action between V. vulnificus Bpt and Aat (Fig. 5, which is published
as supporting information on the PNAS web site, and Supporting
Text).
To identify directly the amino acid residue(s) conjugated by Bpt
to its substrate, Asp-gal was isolated from E. coli (KPS18) that
lacked bothAat andClpA and expressedV. vulnificusBpt, followed
by N-terminal (Edman) sequencing. It revealed the N-terminal
sequence of leucylated Asp-gal, Leu-Asp-gal (Fig. 2F). Thus, V.
vulnificus Bpt, although it recognizes N-terminal Asp and Glu
(similarly to eukaryotic ATE1), conjugates Leu (Ndp in both
prokaryotes and eukaryotes) to these residues, in contrast to
eukaryotic ATE1, which conjugates Arg (Fig. 1 A and C). The
recognitionconjugation specificity of V. vulnificus Bpt was inde-
pendently confirmed by using in vitro conjugation assays with either
3H-Leu or 3H-Arg and either -casein (bearing N-terminal Lys) or
bovine -lactalbumin (bearing N-terminal Glu) as reporters (Fig.
3A). In addition, the enzymatic specificity of strong sequelogs (32)
of V. vulnificus Bpt from other prokaryotes, such as the plant
pathogen Agrobacterium tumefaciens and the plant symbyont Me-
sorhizobium loti was found to be indistinguishable from that of V.
vulnificusBpt (Fig. 3A).We conclude thatBpt proteins are a distinct
class of prokaryotic aa-transferases, termed LD,E-transferases,
which exhibit a hybrid (prokaryoticeukaryotic) specificity. It is
likely (but remains to be determined) that a Bpt LD,E-transferase
can also leucylate an oxidized N-terminal Cys, analogously to the
arginylation of this residue by RD,E,C*-transferases (Fig. 1 A and C)
(11, 18).
Conserved Tyrosines and Cysteines Essential for Bpt Activity. Se-
quence alignments of Bpt proteins revealed strong conservation of
specific residues (Fig. 6, which is published as supporting informa-
tion on the PNAS web site, and Supporting Text). We mutated the
conserved Tyr-58, Tyr-170, and Tyr-205 in V. vulnificus Bpt to Phe
residues. The resultingBpt-Y58F, Bpt-Y170F, andBpt-Y205Fwere
produced in E. coli KPS22 (lacking Aat and LacZ) and purified,
followed by tests in in vitro conjugation assays with 3H-Leu and
-lactalbumin. Bpt-Y58F lost 70–80% of wild-type Bpt activity
(Fig. 3B). Both Bpt-Y170F and Bpt-Y205F, while retaining detect-
able activity, lost 90% of it (Fig. 3B). CD spectra of the mutant
proteins were similar to that of wild-type Bpt (data not shown),
indicating the absence of strong folding defects. Thus, at least one
of the above Tyr residues may be a part of the Bpt’s active site.
Mutants of Saccharomyces cerevisiae ATE1 that lack N-
terminus-proximal Cys residues are inactive in vitro (38). Two of
these Cys residues of ATE1 were also conserved among Bpt
Fig. 2. The N-end rule pathway in V. vulnificus and E. coli. (A) The V.
vulnificus aat-bpt operon and its derivatives. The ORF encoding the Bpt
aa-transferase begins within the stop codon of the preceding aat ORF. The
nucleotide sequence of the bptORF (including its start codon, in red) is shown
below the diagram. Shown above is the 3 end of aat ORF, including its TGA
stop codon, in red. Also indicated are the lengths of flankingV. vulnificusDNA
fragments in the plasmid insert. (B) Relative enzymatic activities of gal in
Aat-lacking E. coli (TS351) expressing S. cerevisiae UBP1, both aa-transferases
of V. vulnificus (WT), and either Met-gal (M), Lys-gal (K), Arg-gal (R),
Asp-gal (D), Glu-gal (E), or Leu-gal (L), produced from the corresponding
Ub fusions. (C) The same as B but in the absence of V. vulnificus Aat. (D) The
same as B but in the absence of V. vulnificus Bpt. (E) The same as B but in the
absence of V. vulnificus Aat and Bpt. One hundred percent is the (averaged)
activity of Met-gal (M). (F) Determination, through Edman degradation, of
the N-terminal sequence of Asp-gal (derived from Ub-Asp-gal) from E. coli
KPS18 that lacked both Aat and ClpA and expressed V. vulnificus Bpt. The
indicated ratio of Leu-Asp-galAsp-gal refers to the incomplete in vivo
leucylation of (overexpressed) Asp-gal by V. vulnificus Bpt in E. coli, as
detected by Edman sequencing.
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aa-transferases (Fig. 6A). In agreement with S. cerevisiae results
(38) and the above sequelogy-based deductions, the Cys-18 3
Ser mutant of V. vulnificus Bpt was found to be inactive as well
(Fig. 6B). The similarity between prokaryotic Bpt proteins and
eukaryotic ATE1 proteins involves a number of other conserved
residues as well (Fig. 6 A and D).
ATEL1 of Malaria Parasite Is a Sequelog of Prokaryotic Aat Trans-
ferases, but Its Specificity Is That of Eukaryotic ATE1 Transferases.
Another kind of aa-transferase identified in the present work is
encoded by the genome of P. falciparum. This eukaryote is an
obligatory intracellular parasite and the cause of malaria in humans
(39). BLASTP with E. coliAat as a query predicted, with a moderate
but statistically significant E-value of 7e-4, that P. falciparum may
encode an aa-transferase (NP473045.1) that is sequelogous to
prokaryotic Aat transferases (LFK,R-transferases). In contrast, the
sequenced genomes of mammalian and arthropod species (includ-
ing the hosts ofP. falciparum) lack significant sequelogs ofAat (data
not shown). Sequelogs of prokaryotic Aat are also present in other
Plasmodium species (P. yoelii yoelii, P. chabaudi, and P. berghei),
with comparable but stronger E-values (4e-7, 1e-6 and 2e-6, re-
spectively, using E. coli Aat as a query).
To determine the conjugationrecognition specificity of the
putative aa-transferase of P. falciparum, it was produced in E. coli
(lacking aat) and purified, followed by in vitro conjugation assays
with either 3H-Leu or 3H-Arg and appropriate reporters. The
specificity of the P. falciparum aa-transferase was found to be
indistinguishable from that of ‘‘canonical’’ eukaryotic ATE1s (Figs.
1 and 3C), despite the absence of significant sequelogy to ATE1s.
The P. falciparum aa-transferase is thus a RE-transferase. We
denoted it, and its strong sequelogs in other species, as ATEL1
(‘‘ATE-like’’), to distinguish this group of R-transferases from
ATE1s and their strong sequelogs Bpt aa-transferases. In vivo
degradation assays with X-gal reporters in E. coli expressing P.
falciparumATEL1 confirmed its specificity forN-terminalGlu, and
in addition indicated that it arginylates N-terminal Asp (data not
shown). Thus, P. falciparumATEL1 is a RD,E-transferase (Fig. 1D).
Identical Specificities of ATE1 and ATEL1 May Be the Result of
Convergent Evolution. PSI-BLAST with S. cerevisiae ATE1 as a query
did not retrieve sequelogs of ATE1 in Plasmodium and related
genomes. A converse PSI-BLAST, with P. falciparum ATEL1 as a
query, did not retrieve sequelogs in eukaryotic genomes known to
encode ATE1 enzymes. Strong sequelogs of Bpt LD,E-transferases
were found only in prokaryotes, where Bpt proteins are frequent in
proteobacteria, except for enterobacteria and other prokaryotes
that have undergone genome reduction as a result of their obliga-
tory parasitism or symbiosis. Eukaryotes are the only organisms
that contain strong sequelogs of mouseyeast ATE1s, in that
prokaryotic Bpt aa-transferases (LD,E-transferases) were much less
sequelogous (32) to ATE1s of eukaryotes than the latter were
among themselves, in addition to Bpt proteins being 2-fold
smaller than eukaryotic ATE1s (for details, see the legend to Fig.
7, which is published as supporting information on the PNAS web
site).
To clarify evolutionary links among aa-transferases, we carried
out phylogenetic analyses of ATE1, ATEL1, Aat, and Bpt (Figs. 4
and 7 and Supporting Text), using both parsimony and distance
analyses. The resulting phylogenetic trees were consistent with each
other (Figs. 4 and 7).We also tested theAatATEL1 family and the
BptATE1 family for sequelogy (32) to each other (Fig. 6), because
even marginally significant sequelogy between them would be
consistent with their (remote) homology. Prokaryotic Bpt LD,E-
transferases and eukaryotic ATE1 RD,E,C*-transferases (Fig. 1)
were clearly sequelogous (Fig. 6 A andD), strongly suggesting their
homology. However, we could not detect sequelogy between pro-
karyotic Aat LFK,R-transferases and Bpt LD,E-transferases (data
not shown), even though both Aat and Bpt conjugate Leu to their
substrates’ N-terminal residues (Fig. 1 B and C). In contrast, the
prokaryoticeukaryotic AatATEL1 aa-transferases and, sepa-
rately, the prokaryoticeukaryotic BptATE1 aa-transferases form
two strongly coherent phylogenetic groups within each protein
family (Figs. 4 and 7). Thus, phylogenetic analyses suggest that
ancestor proteins of P. falciparum (eukaryotic) ATEL1 were de-
rived from prokaryotic Aat aa-transferases rather than from an-
cestors of eukaryotic ATE1s, and that the identical substrate
specificities of the contemporary ATE1s andATEL1s (Fig. 1A and
D) may be the result of convergent evolution. Examples of such
evolution, where nonsequelogous, nonspalogous (32) enzymes (see
Introduction for definitions of terms) have similar enzymatic prop-
erties and physiological functions, include arsenate reductases (40)
and vitamin B6-dependent enzymes (41).
The distribution of AatATEL1 and BptATE1 proteins in
extant organisms is striking in its unevenness. Although many
proteobacterial genomes encode both Aat and Bpt aa-transferases,
other bacteria have only Aat or only Bpt, and no detectable Aat or
Bpt exist in archaea. ATE1 genes are present in a broad set of
‘‘better-known’’ eukaryotes, such as fungi, plants, animals, and
protists. However, we found that ATEL1-like proteins, while ap-
parently absent from the above eukaryotes, are also distributed
broadly among other eukaryotes, such as apicomplexans, leishma-
nias, trypanosomes, cnidaria, diatoms, dinoflagellates, and oomy-
cetes (see Fig. 7 for details). These patterns are consistent with the
hypothesis that aa-transferases arose twice, independently, in a
common ancestor of proteobacteria and eukaryotes, and under-
went two kinds of evolutionary changes in the eukaryotic lineage.
First, ATE1 and ATEL1 independently evolved to function as
R-transferases (rather than L-transferases, their presumed ances-
tral states). Second, either ATE1 or ATEL1 were lost from various
Fig. 3. Enzymatic specificities of V. vulnificus Bpt and P. falciparum ATEL1
aa-transferases. (A) (Left) 3H-Leu: lane 1, purified V. vulnificus Bpt was incu-
bated with 3H-Leu, other components of the aa-transferase assay, and the
14-kDa bovine -lactalbumin (bearing N-terminal Glu) as a reporter. Lanes
2–5, the same as lane 1 but with A. tumefaciens Bpt, M. loti Bpt, S. cerevisiae
ATE1, and E. coli Aat, respectively. Lanes 6–10, the same as lanes 1–5 but with
the 24-kDa bovine -casein (bearing N-terminal Lys) as a reporter. (Right)
3H-Arg: the same as Left but with 3H-Arg instead of 3H-Leu. Arrows indicate
the bands of 3H-lactalbumin and 3H-casein, and numbers to the left indicate
molecular masses, in kDa, of protein standards. (B) Relative enzymatic activ-
ities of V. vulnificus Bpt in which specific Tyr residues were converted to Phe.
Purified mutant and WT V. vulnificus Bpt (0.2 g each) were assayed in vitro
with 3H-Leu as described in SupportingText, using-lactalbumin as a reporter.
3H was measured in triplicate samples, and the data were corrected by
subtracting 3H incorporation in the control assay lacking Bpt. (C) aa-
transferase assay with purified (0.25 g) P. falciparum ATEL1 enzyme in the
presence of either -casein or -lactalbumin and either 3H-Leu or 3H-Arg as
indicated.








deep lineages of eukaryotes, so that extant eukaryotes contain one
of them, but apparently not both. Larger sets of sequenced ge-
nomes, particularly of underexplored unicellular eukaryotes, and
specificity comparisons of their aa-transferases would be required
to verify the above scenario.
On the Functions of Prokaryotic N-End Rule Pathways. In addition to
proteomic and genetic approaches to the pathway’s function(s)
in prokaryotes, one might extrapolate from its known functions in
eukaryotes. For example, in S. cerevisiae (and possibly also in
multicellular eukaryotes) the N-end rule pathway is the controller
of peptide import, through the regulated degradation of CUP9, a
transcriptional repressor ofPTR2, which encodes themain importer
of dipeptides and tripeptides in yeast (8, 9). The discovery of this
positive-feedback circuit, which takes advantage of the multiple
substrate-binding sites ofUBR1, yielded a plausible scenario of how
the ‘‘peptide-sensing’’ properties of the N-end rule pathway could
either coevolve with peptide-import systems or be ‘‘recruited’’ by
them in the course of evolution (8, 9). It remains to be determined
whether prokaryoticN-end rule pathways are involved in regulating
transmembrane import or export of specific compounds.
Another function of the eukaryotic N-end rule pathway is fidelity
of chromosome segregation, through the degradation of a condi-
tionally produced fragment of a subunit of cohesin, an oligomeric
protein whose chromosome-associated molecules hold together
sister chromatids (19, 42). Might the segregation of prokaryotic
chromosomes andor plasmids also involve a cleavage event that
produces a protein fragment whose degradation by the N-end rule
pathway is functionally relevant? To the best of our knowledge, no
evidence either suggests or precludes this possibility in prokaryotes.
Many protein-size and peptide-size toxic polypeptides that are
capable of entering eukaryotic or prokaryotic cells bear destabi-
lizing N-terminal residues and would be, thus, potential N-end rule
substrates that might be modified by aa-transferases andor de-
graded by the N-end rule pathway. These polypeptides include, in
particular, bacteriocins such as colicins, eukaryotic toxins such as,
for example, ricin, and some of the yeast killer toxins, as well as a
large variety of naturally toxic peptide-size polypeptides that can
enter the cytosol of prokaryotic or eukaryotic cells (43, 44).
Concluding Remarks. The hierarchic organization of N-end rules,
i.e., their tertiary, secondary, and primary destabilizing N-terminal
residues, is a feature more conserved in evolution than either the
Ub dependence of N-end rule pathways or the specificity of
enzymatic reactions that modify destabilizing residues (Fig. 1) (7,
11, 25). For example, the identities of Nds can be different between
prokaryotic and eukaryotic N-end rule pathways (Fig. 1 A and B).
The apparent confinement of Leu-conjugating aa-transferases (Bpt
and Aat) to prokaryotes and Arg-conjugating aa-transferases
(ATE1 and ATEL1) to eukaryotes (Fig. 1) suggests that Arg
became a Ndp residue late in evolution of the N-end rule pathway,
after the emergence of eukaryotes. The absence of sequelogy (32)
between the yeast (S. cerevisiae) NTA1 N-terminal amidase (Nt-
amidase) and the mammalian Asn-specific NTAN1 NtN-amidase
(15, 16) suggests that the tertiary destabilizing N-terminal residues
Asn andGln (Fig. 1A) becamepart of theN-end rule still later, after
the divergence of fungal and metazoan lineages.
ClpS, a 12-kDa adaptor protein specific for the prokaryotic
ClpAP protease (27, 28, 30), contains a region of sequelogy to a
conserved sequence of the much larger UBR1 and other E3 Ub
ligases (N-recognins) of the eukaryoticN-end rule pathway (12, 45).
ClpS is the N-recognin of the E. coli N-end rule pathway, where it
binds to theNdp residues Leu, Phe, Trp, or Tyr (31). ClpS also binds
to the ClpA subunits of ClpAP and thereby functions as an adaptor
in mediating the processive degradation of N-end rule substrates by
ClpAP (31). The targeting layout of prokaryotic N-end rule sub-
strates (specifically, the N-recognin ClpS and its ligand the ClpAP
protease) is thus analogous (distantly homologous?) to that of
eukaryotic N-end rule substrates, specifically, the N-recognin Ub
ligase UBR1 and the 26S proteasome, including the UBR1–
proteasome interaction (46). But the former machine, ClpS–
ClpAP, does not involve Ub (Fig. 1B).
The ancient origins of the N-end rule pathway (it appears to
predate the Ub system, of which it is a part in eukaryotes), its
presence in both eukaryotes and prokaryotes, the code-like nature
of the N-end rule, and the diversity of proteins that either produce
or target specific N-degrons may make this pathway especially
useful in phylogenetic analyses, including reconstructions of early
cellular life. Being a ‘‘bridge’’ between eukaryotes and prokaryotes,
the N-end rule pathway (Fig. 1) may also help understand the
unexplained contrast between the massive size (1,000 genes in a
mammal) and broad functions of the Ub system in eukaryotes and
the absence of this system in prokaryotes. The latter contain
proteins with the characteristic Ub fold but lack the isopeptide
bond-mediated ubiquitylation and Ub itself. The resulting dichot-
omy is striking, because it does not result from any obvious
deficiency in prokaryotic protein degradation, in that the processive
proteolysis in prokaryotes is mechanistically sophisticated and
efficacious (27–31).
The origins of Ub and ubiquitylation in eukaryotes remain
unclear. One idea (A.V., unpublished work) is that primordial Ub
Fig. 4. Parsimony-based phylogenetic analyses of selected BptATE1 and
AatATEL1 aa-transferases. (A) Phylogeny of Bpt and ATE1. (B) Phylogeny of
Aat and ATEL1. Numbers by the phylogenetic branchpoints give their statis-
tical strength, with 100 being a maximum score. See the text and Supporting
Text for details, including the complete names of the indicated organisms.
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(a protein containing theUb fold) emerged (before the appearance
of eukaryotes) as an N-terminal cotranslational chaperone of very
early (suboptimally folding) proteins, playing a role analogous to
the one that modern Ub appears to play as a cotranslational
chaperone of two specific ribosomal proteins (48). The chaperone
function of primordial Ub might account for its initial spread
through positive selection, before the appearance of Ub-specific
enzymes.Apart from the known similarities between the eukaryotic
26S proteasome and its prokaryotic counterparts such as ClpAP (5,
27, 28, 30), the functional analogy (as well as sequelogy) between
the prokaryotic N-recognin ClpS and the N-recognins (Ub ligases)
of the eukaryotic N-end rule pathway (31) is unique so far, to the
best of our knowledge, in linking the processive proteolysis in
prokaryotes and the Ub system in eukaryotes.
Materials and Methods
Construction of E. coli Mutants.The strains andplasmids used, aswell
as their construction, are described in Supporting Text and Tables
1 and 2, which are published as supporting information on the
PNAS web site.
Cloning and Alterations of the V. vulnificus aat-bpt Operon. The
plasmid pEG16 (which contained the aat-bpt operon) and its
deletion derivatives were constructed as described in Supporting
Text.
Plasmids Expressing X-gal Reporters and UBP1. pUB23-X plasmids
encoding Ub-X-gal fusion proteins (35, 49) were converted into
plasmids that coexpressed these fusions and the S. cerevisiaeUBP1
deubiquitylating enzyme, as described in Supporting Text.
Assays for gal Activity and N-Terminal Sequencing of X. These
procedures were carried out as described in Supporting Text.
Expression and Purification of aa-Transferases. See Supporting Text
for description of the cloning of the E. coli aat, V. vulnificus bpt,
M. loti bpt, A. tumefaciens bpt, and P. falciparum ATEL1 genes,
their expression in specific E. coli strains, and purification of the
corresponding enzymes.
Site-Directed Mutagenesis of V. vulnificus Bpt.Mutated alleles of the
V. vulnificus bpt gene were obtained as described in Supporting Text,
followed by expression and purification of the mutant Bpt proteins.
In Vitro aa-Transferase Assays. The reporter substrates were either
-casein (with N-terminal Lys, a substrate of E. coliAat) or bovine
-lactalbumin (with N-terminal Glu, a substrate of S. cerevisiae
ATE1). Specific aa-transferases were incubated with substrates in
the presence of either 3H-Leu or 3H-Arg and components (includ-
ing ATP, tRNAs and aminoacyl-tRNA synthetases) that enabled
the amino acid–protein conjugation, followed by SDSPAGE and
autoradiography.
Phylogenetic Analysis. Searches for sequelogs (32) of specific aa-
transferases were carried out with BLASTP, TBLASTN, or PSI-BLAST.
Multiple sequence alignments were produced by using PROBCONS.
Phylogenetic analyses were carried out with PHYLIP. See Supporting
Text for references and details.
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